Data Sheet 4_Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials.pdf

This meta-analysis evaluates its preventive efficacy and administration regimens.</p>Methods<p>PubMed, EMBASE, and the Cochrane Library were searched from database inception to a prespecified cutoff of June 1, 2025; final electronic searches were run on June 8, 2025, to identify randomized controlled trials (RCTs) comparing perioperative intravenous lidocaine with placebo/standard care in adults.

Primary outcomes were CPSP incidence at 3 and 6 months postoperatively.</p>Results<p>Eighteen RCTs (1,391 patients) were included. Intravenous lidocaine significantly reduced CPSP incidence (RR = 0.67; 95% CI: 0.53 to 0.85; P = 0.001) and neuropathic pain risk (RR = 0.60; 95% CI: 0.43 to 0.85; P = 0.004) at 3 months. However, the reduction in the incidence of CPSP was not statistically significant at 6 months (RR = 0.68; 95% CI: 0.41 to 1.12; P = 0.13).